LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article ; Online: Identification of Medication-Related Risks in Bariatric Surgery Patients by Performing Structured Medication Reviews.

    Böhm, Doortje T M M / Berghuis, Kim / Said, Mohammed / Kerskes, Marieke C H M / Deenen, Maarten J / Bastiaans, Diane E T

    Obesity surgery

    2023  Volume 33, Issue 12, Page(s) 3932–3937

    Abstract: Purpose: More medication-related issues are seen with the growing demand for bariatric surgery, because of possible altered pharmacokinetics after surgery. Collaboration with a pharmacist could improve the short- and long-term safety and efficacy of ... ...

    Abstract Purpose: More medication-related issues are seen with the growing demand for bariatric surgery, because of possible altered pharmacokinetics after surgery. Collaboration with a pharmacist could improve the short- and long-term safety and efficacy of pharmacotherapy in patients undergoing bariatric surgery. The aim of this study was to evaluate the impact of a structured medication review to identify medication-related risks before bariatric surgery.
    Materials and methods: The impact on pharmacy-led interventions of introducing a structured medication review was evaluated in a historically controlled study. In the retrospective part, we evaluated patient characteristics, medication use, and number of pre-surgery consultations with a pharmacist before the introduction of medication reviews. A flowchart was developed to detect the use of medicines with risks associated with bariatric surgery. In the prospective part, we evaluated pharmacy-led interventions after the introduction of structured medication reviews using the flowchart. Outcome effectiveness was measured through the number of pre-surgery pharmacy-led interventions.
    Results: Before using the flowchart for screening on risk medicines, 40 (2.6%) pharmacy-led interventions were identified in 1536 patients. In the prospective group, 195 patients were included and 88 (45%) interventions were identified (p < 0.001).
    Conclusion: A structured medication review before bariatric surgery significantly increased the number of pharmacy-led interventions in bariatric surgery patients. This procedure will shift interventions to pre-surgery instead of post-surgery, contributing to the optimization of pharmacotherapy at an early stage.
    MeSH term(s) Humans ; Medication Review ; Retrospective Studies ; Obesity, Morbid/surgery ; Bariatric Surgery ; Pharmaceutical Services
    Language English
    Publishing date 2023-10-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-023-06889-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3381: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The role of formulation on the pharmacokinetics of antiretroviral drugs.

    Bastiaans, Diane E T / Cressey, Tim R / Vromans, Herman / Burger, David M

    Expert opinion on drug metabolism & toxicology

    2014  Volume 10, Issue 7, Page(s) 1019–1037

    Abstract: Introduction: A multitude of antiretroviral drug formulations are now available for HIV-infected adults and children. These formulations include individual and co-formulated drugs, many of which are also supplied in generic versions. Many antiretroviral ...

    Abstract Introduction: A multitude of antiretroviral drug formulations are now available for HIV-infected adults and children. These formulations include individual and co-formulated drugs, many of which are also supplied in generic versions. Many antiretroviral drugs have a low aqueous solubility and poor bioavailability. Drug formulation can significantly affect bioavailability, and given the increasing number of new formulations and drug combinations, it is important to be aware that formulation can influence the pharmacokinetics of antiretroviral drugs.
    Areas covered: This review provides an overview of studies assessing the pharmacokinetics of different antiretroviral drug formulations in adults and children, including fixed-dose combinations. For some antiretroviral drugs, differences in pharmacokinetics have been described, with largest differences in exposure when a liquid formulation is compared to a tablet or capsule formulation. Biopharmaceutical properties of antiretroviral drugs relevant to bioavailability are discussed.
    Expert opinion: Antiretroviral drug formulations and their excipients can significantly impact drug exposure. However, this is not yet fully recognized. It is important to realize that children use different formulations than adults. Effort should be made to ensure that adequate drug exposures are achieved to treat HIV-infected children. In addition, manipulation of drug formulations may lead to differences in pharmacokinetics.
    MeSH term(s) Adult ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/pharmacokinetics ; Anti-HIV Agents/therapeutic use ; Biological Availability ; Chemistry, Pharmaceutical ; Child ; Drug Combinations ; Drug Therapy, Combination ; Drugs, Generic/pharmacokinetics ; Excipients/chemistry ; HIV Infections/drug therapy ; Humans ; Solubility
    Chemical Substances Anti-HIV Agents ; Drug Combinations ; Drugs, Generic ; Excipients
    Language English
    Publishing date 2014-07
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2214462-6
    ISSN 1744-7607 ; 1742-5255
    ISSN (online) 1744-7607
    ISSN 1742-5255
    DOI 10.1517/17425255.2014.925879
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6264: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Zileuton for Pruritus in Sjögren-Larsson Syndrome: A Randomized Double-blind Placebo-controlled Crossover Trial.

    Fuijkschot, Joris / Seyger, Marieke M B / Bastiaans, Diane E T / Wevers, Ron A / Roeleveld, Nel / Willemsen, Michèl A A P

    Acta dermato-venereologica

    2016  Volume 96, Issue 2, Page(s) 255–256

    MeSH term(s) Adolescent ; Adult ; Antipruritics/adverse effects ; Antipruritics/therapeutic use ; Child ; Double-Blind Method ; Female ; Humans ; Hydroxyurea/adverse effects ; Hydroxyurea/analogs & derivatives ; Hydroxyurea/therapeutic use ; Male ; Netherlands ; Pruritus/diagnosis ; Pruritus/drug therapy ; Pruritus/etiology ; Sjogren's Syndrome/complications ; Sjogren's Syndrome/diagnosis ; Time Factors ; Treatment Outcome ; Young Adult
    Chemical Substances Antipruritics ; zileuton (V1L22WVE2S) ; Hydroxyurea (X6Q56QN5QC)
    Language English
    Publishing date 2016-02
    Publishing country Sweden
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 80007-7
    ISSN 1651-2057 ; 0001-5555
    ISSN (online) 1651-2057
    ISSN 0001-5555
    DOI 10.2340/00015555-2195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.101: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.

    Bastiaans, Diane E T / Geelen, Sibyl P M / Visser, Eline G / van der Flier, Michiel / Vermont, Clementien L / Colbers, Angela P H / Roukens, Monique / Burger, David M / van Rossum, Annemarie M C

    The Pediatric infectious disease journal

    2018  Volume 37, Issue 10, Page(s) 1008–1010

    Abstract: In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir/ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 ... ...

    Abstract In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir/ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.
    MeSH term(s) Child ; Darunavir/administration & dosage ; Darunavir/pharmacokinetics ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; HIV Infections/drug therapy ; HIV Protease Inhibitors/administration & dosage ; HIV Protease Inhibitors/pharmacokinetics ; HIV-1/drug effects ; Humans ; Male ; Ritonavir/administration & dosage ; Ritonavir/pharmacokinetics
    Chemical Substances HIV Protease Inhibitors ; Ritonavir (O3J8G9O825) ; Darunavir (YO603Y8113)
    Language English
    Publishing date 2018-02-23
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Validation Studies
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0000000000001964
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1852: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia.

    Bastiaans, Diane E T / Swart, Eleonora L / van Akkeren, Jesse P / Derijks, Luc J J

    International journal of clinical pharmacy

    2012  Volume 35, Issue 2, Page(s) 210–216

    Abstract: Background: Patients who remain comatose after resuscitation are treated with moderate hypothermia. Little is known about the pharmacokinetics of drugs in patients who are treated with moderate hypothermia.: Objective: We investigated the ... ...

    Abstract Background: Patients who remain comatose after resuscitation are treated with moderate hypothermia. Little is known about the pharmacokinetics of drugs in patients who are treated with moderate hypothermia.
    Objective: We investigated the pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia in comparison to normothermic and non-resuscitated patients.
    Setting: This study was performed on the ICU of a Dutch non-academic hospital. The study population consisted of nine patients in the hypothermic group and eight patients in the control group.
    Method: The resuscitated patients were cooled to a target temperature of 33 °C and rewarmed 24 h after start of cooling. Midazolam was given as continuous infusion. The control group consisted of non-resuscitated ICU-patients who were treated with midazolam as sedative. Plasma concentration-time data were collected for midazolam and its metabolites.
    Main outcome measure: Non-linear mixed effect modelling was used to analyze midazolam population pharmacokinetics and identify possible covariates.
    Results: A two-compartment pharmacokinetic model best describes the data. The pharmacokinetic models of the investigated groups are not significantly different. Pharmacokinetic parameter estimates for midazolam for the hypothermic group are a body clearance (CL) of 12.6 l/h, an apparent volume of the central compartment (V1) of 19.1 l, an apparent volume of the peripheral compartment (V2) of 108 l and an intercompartmental clearance (Q) of 18.4 l/h. Estimated parameters for the control group are CL of 14.2 l/h, a V1 of 15.7 l, a V2 of 171 l and Q of 25.6 l/h. In the covariate analysis, body temperature did not significantly improve the model.
    Conclusion: We found no significant difference in the pharmacokinetics of midazolam between resuscitated patients treated with hypothermia during 24 h and the control group.
    MeSH term(s) Aged ; Coma/therapy ; Female ; Humans ; Hypnotics and Sedatives/pharmacokinetics ; Hypothermia, Induced/methods ; Intensive Care Units ; Male ; Midazolam/pharmacokinetics ; Middle Aged ; Models, Biological ; Netherlands ; Nonlinear Dynamics ; Prospective Studies ; Resuscitation ; Temperature ; Tissue Distribution
    Chemical Substances Hypnotics and Sedatives ; Midazolam (R60L0SM5BC)
    Language English
    Publishing date 2012-11-29
    Publishing country Netherlands
    Document type Controlled Clinical Trial ; Journal Article
    ZDB-ID 2601204-2
    ISSN 2210-7711 ; 2210-7703 ; 0928-1231
    ISSN (online) 2210-7711
    ISSN 2210-7703 ; 0928-1231
    DOI 10.1007/s11096-012-9725-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir.

    Bastiaans, Diane E T / Immohr, Laura I / Zeinstra, Gertrude G / Strik-Albers, Riet / Pein-Hackelbusch, Miriam / van der Flier, Michiel / de Haan, Anton F J / Boelens, Jaap Jan / Lankester, Arjan C / Burger, David M / Warris, Adilia

    British journal of clinical pharmacology

    2017  Volume 83, Issue 12, Page(s) 2789–2797

    Abstract: Aims: The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the new paediatric formulation (test formulation) compared to the reference formulation was investigated.: Methods: ... ...

    Abstract Aims: The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the new paediatric formulation (test formulation) compared to the reference formulation was investigated.
    Methods: In vivo palatability testing was performed in a randomized, two-period, multicentre, cross-over study. Children and their parents scored the liking of the new paediatric valaciclovir formulation and the reference formulation on a 100 mm visual analogue scale (VAS). To support formulation development and palatability testing, electronic tongue measurements were applied.
    Results: The electronic tongue measurement indicated taste-masking capabilities for three different formulations in the developmental phase. A glycerol-based formulation was further tested and compared to the reference formulation prepared out of crushed and suspended tablets. The mean difference (95% CI) in VAS scores between both formulations, as indicated by the children (n = 20), was 2.4 (-8.5, 13) mm, in favour of the new paediatric valaciclovir formulation. The mean (95% CI) difference in VAS scores indicated by the parents (n = 20) was -0.9 (-12, 9.8) mm.
    Conclusion: The palatability of the new paediatric valaciclovir formulation was considered non-inferior to the reference formulation prepared out of crushed tablets. We were able to optimize the study design and number of children to be included in the palatability testing by using electronic tongue measurements.
    MeSH term(s) Acyclovir/administration & dosage ; Acyclovir/adverse effects ; Acyclovir/analogs & derivatives ; Acyclovir/chemistry ; Administration, Oral ; Age Factors ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/chemistry ; Child ; Child, Preschool ; Cross-Over Studies ; Drug Compounding ; Electronic Nose ; Humans ; Netherlands ; Patient Satisfaction ; Perceptual Masking ; Pharmaceutical Solutions ; Tablets ; Taste ; Taste Perception ; Valacyclovir ; Valine/administration & dosage ; Valine/adverse effects ; Valine/analogs & derivatives ; Valine/chemistry
    Chemical Substances Antiviral Agents ; Pharmaceutical Solutions ; Tablets ; Valine (HG18B9YRS7) ; Valacyclovir (MZ1IW7Q79D) ; Acyclovir (X4HES1O11F)
    Language English
    Publishing date 2017-09-20
    Publishing country England
    Document type Comparative Study ; Equivalence Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.13396
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1118: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

    Janssen, Esther J H / Bastiaans, Diane E T / Välitalo, Pyry A J / van Rossum, Annemarie M C / Jacqz-Aigrain, Evelyne / Lyall, Hermione / Knibbe, Catherijne A J / Burger, David M

    British journal of clinical pharmacology

    2017  Volume 83, Issue 6, Page(s) 1287–1297

    Abstract: Aim: The objectives of this study were to characterize age-related changes in lamivudine pharmacokinetics in children and evaluate lamivudine exposure, followed by dose recommendations for subgroups in which target steady state area under the daily ... ...

    Abstract Aim: The objectives of this study were to characterize age-related changes in lamivudine pharmacokinetics in children and evaluate lamivudine exposure, followed by dose recommendations for subgroups in which target steady state area under the daily plasma concentration-time curve (AUC
    Methods: Population pharmacokinetic modelling was performed in NONMEM using data from two model-building datasets and two external datasets [n = 180 (age 0.4-18 years, body weight 3.4-60.5 kg); 2061 samples (median 12 per child); daily oral dose 60-300 mg (3.9-17.6 mg kg
    Results: A two-compartment model with sequential zero order and first order absorption best described the data. Apparent clearance and central volume of distribution (% RSE) were 13.2 l h
    Conclusion: Bodyweight best predicted the developmental changes in apparent lamivudine clearance and volume of distribution. For children aged 5 months-18 years with a body weight <14 kg, the dose should be increased from 8 to 10 mg kg
    MeSH term(s) Adolescent ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/pharmacokinetics ; Anti-HIV Agents/therapeutic use ; Area Under Curve ; Biological Availability ; Body Weight ; Child ; Child, Preschool ; Dose-Response Relationship, Drug ; Female ; HIV Infections/drug therapy ; Humans ; Infant ; Lamivudine/administration & dosage ; Lamivudine/pharmacokinetics ; Lamivudine/therapeutic use ; Male ; Models, Statistical ; Population
    Chemical Substances Anti-HIV Agents ; Lamivudine (2T8Q726O95)
    Language English
    Publishing date 2017-02-14
    Publishing country England
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.13227
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1118: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: A new paediatric formulation of valaciclovir: development and bioequivalence assessment.

    Bastiaans, Diane E T / Bartels-Wilmer, Carli M / Colbers, Angela P H / Heijens, Claudia A W / Velthoven-Graafland, Kirsten / Smeets, Oscar S N M / Vink, Nicole / Harbers, Veroniek E M / Warris, Adilia / Burger, David M

    Archives of disease in childhood

    2016  Volume 101, Issue 10, Page(s) 971–972

    MeSH term(s) Acyclovir/administration & dosage ; Acyclovir/adverse effects ; Acyclovir/analogs & derivatives ; Acyclovir/pharmacokinetics ; Administration, Oral ; Adult ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/pharmacokinetics ; Biological Availability ; Child ; Cross-Over Studies ; Drug Compounding/methods ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Female ; Humans ; Male ; Pharmaceutical Solutions ; Tablets ; Therapeutic Equivalency ; Valacyclovir ; Valine/administration & dosage ; Valine/adverse effects ; Valine/analogs & derivatives ; Valine/pharmacokinetics
    Chemical Substances Antiviral Agents ; Pharmaceutical Solutions ; Tablets ; Valine (HG18B9YRS7) ; Valacyclovir (MZ1IW7Q79D) ; Acyclovir (X4HES1O11F)
    Language English
    Publishing date 2016-05-09
    Publishing country England
    Document type Clinical Trial, Phase I ; Letter ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 524-1
    ISSN 1468-2044 ; 0003-9888 ; 1359-2998
    ISSN (online) 1468-2044
    ISSN 0003-9888 ; 1359-2998
    DOI 10.1136/archdischild-2015-310266
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Um IV Zs.106: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MA 3: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.

    Gondrie, Ivar P E / Bastiaans, Diane E T / Fraaij, Pieter L A / Driessen, Gertjan J A / van der Knaap, Linda C / Visser, Eline G / van Jaarsveld, Petronette / de Groot, Ronald / Hartwig, Nico G / Burger, David M / van Rossum, Annemarie M C

    The Pediatric infectious disease journal

    2017  Volume 36, Issue 10, Page(s) 976–980

    Abstract: Background: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children. Good short-term clinical, virologic and immunologic outcomes have been observed in children on LPV/r QD.: Methods: We evaluated the long-term ... ...

    Abstract Background: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children. Good short-term clinical, virologic and immunologic outcomes have been observed in children on LPV/r QD.
    Methods: We evaluated the long-term effectiveness of a LPV/r QD containing regimen in HIV-1-infected children in clinical practice. Selected children (0-18 years of age) with an undetectable HIV-1 RNA viral load (<50 copies/mL) for at least 6 months on a twice-daily LPV/r-containing regimen switched to LPV/r QD. The main outcome measures were the percentage of patients with an undetectable HIV-1 viral load each subsequent year after switch to LPV/r QD (on treatment and last observation carried forward), and virologic failure during follow-up (>400 copies/mL twice within 6 months). Also, the exposure to LPV on the initial once-daily dosing regimen was determined.
    Results: Forty children (median age: 6.5 years; range: 1.0-17) were included. Median follow-up was 6.3 years (range: 1.0-10.3). During yearly follow-up, the percentage of children with an undetectable viral load varied between 82% and 100% (on treatment) and 83% and 93% (last observation carried forward). Five children (12.5%) met the criteria for failure. CD4+ and CD8+ counts remained stable at normal values. Geometric mean LPV area under the plasma concentration-time curve (linear up-log down method) over a dosing interval from time 0 to 24 hours after dosing was 169.3 mg x h/L, and last observed drug concentration was 1.35 mg/L. Adverse events were encountered in 8 patients, were mainly gastrointestinal, and in these cases, no reason to stop treatment.
    Conclusion: A once-daily LPV/r-containing regimen in HIV-1-infected children with intensive clinical and therapeutic drug monitoring is well tolerated and has good long-term clinical, virologic and immunologic outcomes.
    MeSH term(s) Adolescent ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/therapeutic use ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV-1 ; Humans ; Infant ; Kaplan-Meier Estimate ; Lopinavir/administration & dosage ; Lopinavir/adverse effects ; Lopinavir/therapeutic use ; Male ; Ritonavir/administration & dosage ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; Sustained Virologic Response ; Viral Load
    Chemical Substances Anti-HIV Agents ; Lopinavir (2494G1JF75) ; Ritonavir (O3J8G9O825)
    Language English
    Publishing date 2017-10
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0000000000001627
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1852: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir

    Bastiaans, Diane E.T. / Immohr, Laura I. / Zeinstra, Gertrude G. / Strik-Albers, Riet / Pein-Hackelbusch, Miriam / van der Flier, Michiel / de Haan, Anton F.J. / Boelens, Jaap Jan / Lankester, Arjan C. / Burger, David M. / Warris, Adilia

    British Journal of Clinical Pharmacology

    2017  Volume 83, Issue 12

    Abstract: Aims: The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the new paediatric formulation (test formulation) compared to the reference formulation was investigated. Methods: In ... ...

    Abstract Aims: The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the new paediatric formulation (test formulation) compared to the reference formulation was investigated. Methods: In vivo palatability testing was performed in a randomized, two-period, multicentre, cross-over study. Children and their parents scored the liking of the new paediatric valaciclovir formulation and the reference formulation on a 100 mm visual analogue scale (VAS). To support formulation development and palatability testing, electronic tongue measurements were applied. Results: The electronic tongue measurement indicated taste-masking capabilities for three different formulations in the developmental phase. A glycerol-based formulation was further tested and compared to the reference formulation prepared out of crushed and suspended tablets. The mean difference (95% CI) in VAS scores between both formulations, as indicated by the children (n = 20), was 2.4 (-8.5, 13) mm, in favour of the new paediatric valaciclovir formulation. The mean (95% CI) difference in VAS scores indicated by the parents (n = 20) was -0.9 (-12, 9.8) mm. Conclusion: The palatability of the new paediatric valaciclovir formulation was considered non-inferior to the reference formulation prepared out of crushed tablets. We were able to optimize the study design and number of children to be included in the palatability testing by using electronic tongue measurements.
    Keywords Drug development ; Infectious diseases ; Paediatrics ; Pharmacotherapy ; Quality use of medicines
    Subject code 690
    Language English
    Publishing country nl
    Document type Article ; Online
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1118: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top